Bayer Shares Drop Following Earnings – What Was In The Print

Bayer AG shares (ETR:BAYN) tumbled 4.84% to €36.46 ahead of the close after the German pharmaceutical and chemicals giant reported a dramatic deterioration in profitability for fiscal 2025, with net losses widening to €3.76 billion amid mounting litigation costs and operational challenges across key divisions.

The Leverkusen-based company posted group sales of €11.44 billion for the period, down from €11.73 billion in the prior year, while EBITDA before special items fell sharply to €1.97 billion from €2.35 billion. More alarming for markets was the swing in operating performance, with group EBIT registering a loss of €2.87 billion compared to a profit of €134 million last year. Free cash flow also declined to €2.89 billion from €3.31 billion, while net financial debt stood at €29.84 billion.

CEO Bill Anderson struck a cautiously optimistic tone during the company’s Financial News Conference, stating that Bayer delivered guidance comfortably within the improved corridor. He highlighted progress in the Crop Science division, which advanced in the first year of its profitability improvement program, and noted that the Pharmaceuticals business showed signs of rejuvenation with launch medicines establishing themselves as growth drivers. However, the Consumer Health division suffered from market softness in the United States and China, though it managed to maintain the bottom line.

The earnings release comes as Bayer continues to grapple with substantial legal liabilities related to Roundup, the glyphosate-based herbicide acquired through its 2018 purchase of Monsanto. Last month, the company announced a class settlement agreement to resolve current and future claims, with Monsanto committing to capped annual payments totaling up to $7.25 billion over 21 years, subject to court approval. This multi-pronged litigation strategy is proceeding apace, according to Anderson, and represents a critical element of the company’s turnaround efforts.

Looking ahead to 2026, Bayer expects a year of solid sales and stable earnings on a currency-adjusted basis, projecting revenues of €45 billion to €47 billion, representing a year-on-year change of zero to plus 3% on a currency- and portfolio-adjusted basis. EBITDA before special items is forecast at €9.6 billion to €10.1 billion. The company has updated its core earnings per share methodology to include amortization of certain intangible assets, particularly software, for enhanced transparency. Under this revised approach, currency-adjusted core earnings per share are expected to range between €4.30 and €4.80 in 2026, compared to €4.57 in 2025 using the same methodology.

Significantly, Bayer projects free cash flow of minus €2.5 billion to minus €1.5 billion in 2026, reflecting approximately €5 billion in payouts connected to litigation settlements. Net financial debt is expected to climb to €32 billion to €33 billion by year-end. Anderson acknowledged the company’s current strategic position, noting strong signs of progress but emphasizing that comprehensive turnaround work remains incomplete.

The company continues to implement its Dynamic Shared Ownership initiative, targeting €2 billion in savings through the new operating model. Anderson emphasized that Bayer has a clear picture of what needs to be done in every area, though execution remains paramount.

Markets appear to be weighing the substantial litigation costs against operational improvements, with the sharp decline in share price reflecting concerns over near-term cash flow pressures and the elevated debt burden. The negative free cash flow guidance for 2026, driven primarily by settlement payments, underscores the financial strain these legacy liabilities continue to impose on the business. While management’s strategic initiatives show promise, investor sentiment suggests patience is wearing thin as the turnaround timeline extends.